As both ERBB1 and c-MET have been reported to be upregulated in metastatic ERBB2+ BC and positively correlated with poor survival in ERBB2+ BC patients, these pathways are considered as potential targets for combination therapies of metastatic BC. Here, EGFR is linked to breast cancer.